Citations

Clear

6273 citation(s) found for "To, Andrew".

Factors Associated With the Decision-Making on Endovascular Thrombectomy for the Management of Acute Ischemic Stroke
Saposnik, Gustavo , Menon, Bijoy K. , Kashani, Nima , Wilson, Alexis , Baxter, Blaise, Turjman, Francis , Fischer, Urs , Mitchell, Peter , Sylaja, Pillai N., Cherian, Mathew , Kim, Byung Moon , Heo, Ji Hoe , Podlasek, Anna , Foss, M , Hill, Michael D. , Hill, Michael D , Fischer, Urs , Yoshimura, Shinichi , Campbell, Bruce , Rabinstein, Alejandro A. , Ospel, Johanna M. , Almekhlafi, Mohammed , Demchuk, Andrew M. , Goyal, Mayank

Mayo Clinic

Stroke | July 22, 2019 | Volume: 50 | Issue: 9 | Pages: 2441-2447

10.1161/strokeaha.119.025631 | PMID 31327314 Get It

Background and Purpose— Little is known about the real-life factors that clinicians use in selection of patients that would receive endovascular treatment (EVT) in the real world. We sought to determine patient, practitioner, and health system factors associated with therapeutic decisions around endovascular treatment. Methods— We conducted a multinational cross-sectional web-based study comprising of 607 clinicians and interventionalists from 38 countries who are directly involved in acute stroke care. Participants were randomly allocated to 10 from a pool of 22 acute stroke case scenarios. Each case was classified as either Class I, Class II, or unknown evidence according to the current guidelines. We used logistic regression analysis applying weight of evidence approach. Main outcome measures were multilevel factors associated with EVT, adherence to current EVT guidelines, and practice gaps between current and ideal practice settings. Results— Of the 1330 invited participants, 607 (45.6%) participants completed the study (53.7% neurologists, 28.5% neurointerventional radiologists, 17.8% other clinicians). The weighed evidence approach revealed that National Institutes of Health Stroke Scale (34.9%), level of evidence (30.2%), ASPECTS (Alberta Stroke Program Early CT Score) or ischemic core volume (22.4%), patient’s age (21.6%), and clinicians’ experience in EVT use (19.3%) are the most important factors for EVT decision. Of 2208 responses that met Class I evidence for EVT, 1917 (86.8%) were in favor of EVT. In case scenarios with no available guidelines, 1070 of 1380 (77.5%) responses favored EVT. Comparison between current and ideal practice settings revealed a small practice gap (941 of 6070 responses, 15.5%). Conclusions— In this large multinational survey, stroke severity, guideline-based level of evidence, baseline brain imaging, patients’ age and physicians’ experience were the most relevant factors for EVT decision-making. The high agreement between responses and Class I guideline recommendations and high EVT use even when guidelines were not available reflect the real-world acceptance of EVT as standard of care in patients with disabling acute ischemic stroke.
Use of the subscapular system by maintaining unilateral decubitus placement without repositioning in microvascular free tissue transplantation
Forte, Antonio J. , Oliver, Jeremie D. , McRae, Matthew , Colasante, Cesar , Eells, Annica C. , Watt, Andrew, Buntic, Rudolph, Buncke, Gregory M. , Safa, Bauback , Forte, Antonio Jorge , Oliver, Jeremie D , Watt, Andrew

Mayo Clinic

Microsurgery | July 12, 2019 | Volume: 40 | Issue: 2 | Pages: 125-129

10.1002/micr.30488 | PMID 31298423 Get It

AbstractBackgroundIn microvascular free‐tissue harvest and transfer, the need for repositioning from lateral decubitus position and the inability to use a two‐team approach are major drawbacks of the subscapular system. We present our experience with the subscapular system for upper and lower extremity reconstruction using a two‐team approach without need for repositioning.MethodsWe conducted a retrospective chart review for all patients undergoing free flap transplant based on the subscapular system to the upper or lower extremity at our microsurgical facility from January 1, 2007 to December 31, 2011. Only cases not requiring intraoperative repositioning were included. Sixty‐four patients underwent the two‐team approach (37 upper extremity and 27 lower extremity transplants). Flap types included latissimus dorsi musculocutaneous, partial superior latissimus, dorsal thoracic fascia, serratus, scapular bone, and thoracodorsal artery perforator, either alone or as chimeric flaps. All patients were placed in the lateral decubitus position for the duration of the surgery.ResultsThe ipsilateral subscapular system was used in 16% of cases for lower extremity defects, where the anterior tibial vessels served as recipient vessels. The contralateral subscapular system was used in all remaining cases for upper extremity or the vast majority for lower extremity (84%) defects, where either the superficial femoral, genicular, popliteal, sural, or posterior tibial vessels served as recipient vessels. With the exception of one partial flap loss secondary to infection, all flaps survived.ConclusionsProper lateral decubitus positioning allows for a two‐team approach without compromising safety or outcomes.
Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device
Wood, David , Krajcer, Zvonimir , Sathananthan, Janarthanan , Strickman, Neil E., Metzger, Chris, Fearon, William F. , Aziz, Mark, Satler, Lowell F. , Waksman, Ron , Eng, Marvin H. , Heimansohn, David, Sampson, Andrew, Coady, Paul , Rodriguez, Roberto , Krishnaswamy, Amar , Lee, Jason T. , Ben‐Dor, Itsik , Moainie, Sina L. , Kodali, Susheel , Yadav, Pradeep , Kozak, Mark, Bacharach, J. Michael, Feldman, Ted , Nanjundappa, Aravinda , Bersin, Robert M., Potluri, Srinivasa , Barker, Colin M. , Bernardo, Nelson L. , Lumsden, Alan B. , Dake, Michael D. , Brown, David L. , Maor, Nathaniel, Nardone, Samuel, Webb, John G. , Investigators, on behalf of the SAFE MANTA Study, Kapadia, Samir , Greenbaum, Adam B. , Szerlip, Molly , Chhatriwalla, Adnan K , O’Neill, Brian Patrick , Guerrero, Mayra , Zhang, Ming , Barleben, Andrew R. , Campbell, John , Cohen, David Jonathan , Lauck, Sandra , O’Neill, William W. , Investigators, on behalf of the SAFE MANTA Study

Mayo Clinic

Circulation: Cardiovascular Interventions | July 12, 2019 | Volume: 12 | Issue: 7 | Pages: No page available

10.1161/circinterventions.119.007258 | PMID 31296082 Get It

Background: Open surgical closure and small-bore suture-based preclosure devices have limitations when used for transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or percutaneous thoracic endovascular aortic aneurysm repair. The MANTA vascular closure device is a novel collagen-based technology designed to close large bore arteriotomies created by devices with an outer diameter ranging from 12F to 25F. In this study, we determined the safety and effectiveness of the MANTA vascular closure device. Methods and Results: A prospective, single arm, multicenter investigation in patients undergoing transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or thoracic endovascular aortic aneurysm repair at 20 sites in North America. The primary outcome was time to hemostasis. The primary safety outcomes were accessed site-related vascular injury or bleeding complications. A total of 341 patients, 78 roll-in, and 263 in the primary analysis cohort, were entered in the study between November 2016 and September 2017. For the primary analysis cohort, transcatheter aortic valve replacement was performed in 210 (79.8%), and percutaneous endovascular abdominal aortic aneurysm repair or thoracic endovascular aortic aneurysm repair was performed in 53 (20.2%). The 14F MANTA was used in 42 cases (16%), and the 18F was used in 221 cases(84%). The mean effective sheath outer diameter was 22F (7.3 mm). The mean time to hemostasis was 65±157 seconds with a median time to hemostasis of 24 seconds. Technical success was achieved in 257 (97.7%) patients, and a single device was deployed in 262 (99.6%) of cases. Valve Academic Research Consortium-2 major vascular complications occurred in 11 (4.2%) cases: 4 received a covered stent (1.5%), 3 had access site bleeding (1.1%), 2 underwent surgical repair (0.8%), and 2 underwent balloon inflation (0.8%). Conclusions: In a selected population, this study demonstrated that the MANTA percutaneous vascular closure device can safely and effectively close large bore arteriotomies created by current generation transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, and thoracic endovascular aortic aneurysm repair devices. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02908880.
Esophageal overtubes provide no benefit to safety or technical success in upper gastrointestinal tract endoscopic suturing
Storm, Andrew C. , Matar, Reem , Song, Louis M. Wong Kee , Sawas, Tarek , Buttar, Navtej , Topazian, Mark , Wong Kee Song, Louis M, Bazerbachi, Fateh , Buttar, Navtej S, Abu Dayyeh, Barham K, Matar, Reem , Storm, Andrew C , Vargas, Eric J. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | July 11, 2019 | Volume: 07 | Issue: 07 | Pages: E919-E921

10.1055/a-0953-2152 | PMID 31304237 Get It

Abstract Background and study aim The role of esophageal overtubes in upper gastrointestinal endoscopic suturing is unknown. This study aimed to determine whether overtube use was associated with technical success or adverse events. Patients and methods A retrospective review of consecutive patients who underwent endoscopic suturing for various indications was performed. Results A total of 719 patients underwent endoscopic suturing for various indications, including endoscopic bariatric procedures in 262, stent fixation in 258, defect closure in 190, and hemostasis in nine. An overtube was used in 186 procedures (25.9 %). Technical success was achieved in all cases. Minor mucosal trauma occurred in 15 cases (8.1 %) with use of an overtube, and none without an overtube (P < 0.0001). No full-thickness esophageal perforation or hemorrhage related to overtube use or the suturing device occurred. Conclusions Endoscopic suturing can be performed safely for a variety of indications, including endoscopic bariatric procedures, defect repair, and stent fixation without an esophageal overtube. Minor esophageal mucosal trauma and equipment cost are increased when an overtube is used.
Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).
Diab, Adi , Marcondes, Mario Q., Kotzin, Brian L. , Tagliaferri, Mary , Hoch, Ute , Cattaruzza, Fiore, Zalevsky, Jonathan , Bilen, Mehmet Asım , Gupta, Shilpa , Domingo‐Musibay, Evidio , Borazanci, Erkut , Curti, Brendan D. , Borazanci, Erkut , Li, Yunfeng , Brohl, Andrew S. , Brugarolas, James , Conley, Anthony P. , D'Angelo, Sandra P

Mayo Clinic

Journal of Clinical Oncology | July 11, 2019 | Volume: 37 | Issue: 8_suppl | Pages: 26-26

10.1200/jco.2019.37.8_suppl.26 Get It

26 Background: NKTR-262 is a novel intratumoral prodrug designed to promote tumor antigen release, an immune stimulatory environment, and antigen presentation. NKTR-214 increases CD8+ T cells and NK cells in the tumor microenvironment. The combination of NKTR-262 with NKTR-214 accesses innate and adaptive immunity to provide an abscopal response and systemic tumor immunity. The Phase 1b/2 REVEAL trial is enrolling. Methods: In a 3+3 Phase 1 design, pts who are relapsed/refractory to ≥1 CPI receive escalating doses of intratumoral (IT) NKTR-262 followed by combined q3w treatment of IT NKTR-262 and fixed-dose intravenous (IV) NKTR-214 (0.006 mg/kg). Phase 1 will evaluate PK, safety, efficacy, and determine recommended Phase 2 dose. Scans are conducted every 9 wks (± 1 wk). Peripheral blood (PB) and tumor tissue are collected to measure biomarkers of immune activation. In Phase 2 expansion, NKTR-262 + NKTR-214 ± IV nivolumab (360 mg) will be assessed in specific tumor cohorts of IO-naïve and experienced pts. Results: As of 06 Nov 2018, 11 pts had received at least one cycle of NKTR-262 + NKTR-214 therapy. 7/11 pts were efficacy evaluable with at least one on-treatment scan (4 MEL, 2 SARC, 1 CRC). 2/4 R/R melanoma pts had uPRs with 100% (scan 2) and 40% (scan 1) reductions in target lesions per RECIST 1.1, respectively. Both patients remain on treatment. Two SARC pts had stable disease at scan 1. No pts experienced G3 or higher TRAEs or immune-related adverse events (AEs). Most common G1-2 AEs were transient flu-like symptoms. Gene expression analysis of tumor and PB show dose-dependent induction (4 to 16-fold) of TLR target genes. Consistent with the mechanism of action for NKTR-214, PB flow cytometry shows an average 13-fold increase from baseline in Ki67+ CD8+T cells in 6 pts. Conclusions: NKTR-262 + NKTR-214 engage the immune activation cascade from local tumor antigen production to anti-tumor T cell response. Initial dose levels of NKTR-262 with fixed-dose NKTR-214 were well-tolerated with early evidence of clinical activity. These data support continued evaluation of the combination +/- nivolumab. Clinical trial information: NCT03435640.
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Goadsby, Peter J. , Leone, Massimo , Bardos, Jennifer, Oakes, Tina M. , Millen, Brian A. , Zhou, Chunmei, Dowsett, Sherie A. , Aurora, Sheena K. , Ahn, Andrew H. , Yang, Jyun-Yan, Conley, Robert R., Martinez, James M. , Bardos, Jennifer N, Goadsby, Peter J , Dodick, David W.

Mayo Clinic

New England Journal of Medicine | July 10, 2019 | Volume: 381 | Issue: 2 | Pages: 132-141

10.1056/nejmoa1813440 | PMID 31291515 Get It

Reply to Kollef et al
Schreier, Diana J., Frazee, Erin N. , Rule, Andrew D.

Mayo Clinic

Clinical Infectious Diseases | July 10, 2019 | Volume: 70 | Issue: 7 | Pages: 1521-1521

10.1093/cid/ciz644 | PMID 31297521 Get It

Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype
Basha, Basma, Bryant, Sandra C. , Vrana, Julie A., Reed, Katelyn A. , King, Rebecca L. , Rech, Karen L. , Feldman, Andrew L. , Shi, Min

Mayo Clinic

American Journal of Surgical Pathology | July 8, 2019 | Volume: 43 | Issue: 9 | Pages: 1282-1290

10.1097/pas.0000000000001315 | PMID 31283630 Get It

The 2017 World Health Organization update introduced a new category of nodal peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) defined by expression of at least 2 or 3 TFH markers. Our study assesses the utility of an immunohistochemical panel of 5 TFH markers (CD10, BCL6, PD-1, CXCL13, and ICOS) for identification of TFH phenotype in angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (NOS). Immunohistochemical for the 5 markers was performed on 22 cases of AITL and 29 cases of PTCL-NOS. Cases were reviewed for morphologic features characteristic of AITL. All AITL cases showed expression of ≥2 TFH markers. This panel resulted in reclassification of 41% PTCL-NOS cases to PTCL-TFH. Positive percent agreement for the TFH phenotype is 97% for PD1, 94% for ICOS, 44% for CD10 and CXCL13, and 29% for BCL6. Negative percent agreement for TFH phenotype is 100% for CD10, BCL6, and CXCL13, 82% for ICOS and 71% for PD1. AITL cases were more likely than PTCL-TFH cases to contain expanded CD21-positive follicular dendritic cell meshworks, clear cell cytology and polymorphous inflammatory background; however, there was a significant (P<0.005) Kruskal-Wallis trend in all morphologic variables between the 3 groups suggesting a continuum from PTCL-NOS to PTCL-TFH to AITL. The median number of morphologic features of AITL also correlated significantly with number of TFH markers positive (Spearman coefficient ρ=0.759). In summary, the stain panel chosen will have an impact on cases classified as PTCL-TFH. This entity may exist along a spectrum between PTCL-NOS and AITL.
Association Between Participation and Performance in MOCA Minute and Actions Against the Medical Licenses of Anesthesiologists
Zhou, Yan , Macario, Alex, Keegan, Mark T. , Minhaj, Mohammed , Wang, Ting , Harman, Ann E., Sun, Huaping, Patterson, Andrew J., Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | July 8, 2019 | Volume: 129 | Issue: 5 | Pages: 1401-1407

10.1213/ane.0000000000004268 | PMID 31274598 Get It

BACKGROUND: In January 2016, as part of the Maintenance of Certification in Anesthesiology (MOCA) program, the American Board of Anesthesiology launched MOCA Minute, a web-based longitudinal assessment, to supplant the former cognitive examination. We investigated the association between participation and performance in MOCA Minute and disciplinary actions against medical licenses of anesthesiologists. METHODS: All anesthesiologists with time-limited certificates (ie, certified in 2000 or after) who were required to register for MOCA Minute in 2016 were followed up through December 31, 2016. The incidence of postcertification prejudicial license actions was compared between those who did and did not register and compared between registrants who did and did not meet the MOCA Minute performance standard. RESULTS: The cumulative incidence of license actions was 1.2% (245/20,006) in anesthesiologists required to register for MOCA Minute. Nonregistration was associated with a higher incidence of license actions (hazard ratio, 2.93 [95% confidence interval {CI}, 2.15–4.00]). For the 18,534 (92.6%) who registered, later registration (after June 30, 2016) was associated with a higher incidence of license actions. In 2016, 16,308 (88.0%) anesthesiologists met the MOCA Minute performance standard. Of those not meeting the standard (n = 2226), most (n = 2093, 94.0%) failed because they did not complete the required 120 questions. Not meeting the standard was associated with a higher incidence of license actions (hazard ratio, 1.92 [95% CI, 1.36–2.72]). CONCLUSIONS: Both timely participation and meeting performance standard in MOCA Minute are associated with a lower likelihood of being disciplined by a state medical board.